Sanger Institute and Wellcome Genome Campus temporarily closed to all but critical research
In response to the rapidly changing COVID-19 pandemic, the Sanger Institute and its neighbours on the Wellcome Genome Campus will close all but critical and essential operations from Friday 20 March.
Following careful consideration of the current coronavirus (COVID-19) pandemic, the Sanger Institute and Wellcome Genome Campus will close all but critical and essential operations.
The decision has been made in the interests of the health and wellbeing of the Institute and Campus’ community, including staff, service partners, customers, tenants, contractors and visitors.
The majority of staff are working remotely to ensure continuity of operations, making use of remote communication and collaboration tools.
A small number of staff will remain working on site and will be supported to keep core science running.
Please note that the Sanger Institute will not be accepting samples or deliveries, apart from those related to essential services and projects.
On the wider Campus, the usual programmes of events and visits are suspended until further notice. This includes all courses and conferences, on and off-site public events, and all Conference Centre activites. Dates for restarting various activities will be reviewed on an ongoing basis.
The decision of when to fully re-open the Sanger Institute and Wellcome Genome Campus will be taken in due course, and all announcements will be posted on line.
Please contact staff by email for the quickest response.
For information about EMBL-EBI, please go to: www.ebi.ac.uk
For further information and updates on revised dates of events in the Wellcome Genome Campus Advanced Courses and Scientific Conferences Programme, please visit: https://coursesandconferences.wellcomegenomecampus.org/
16 Apr 2021
Genetic variants identified that impact immune cells' functioning
Researchers have combined genome-wide sequencing and functional profiling of immune cells to understand more about the impact of genetic variants on ...
12 Apr 2021
New genetic drug target for treatment resistant colorectal cancer
Researchers have identified a new potential drug target for treating some types of advanced colorectal cancers.